Amoy Diagnostics News

Amoy Diagnostics (300685.SZ): has obtained the invention patent certificate.

Gelonghui, on December 13th, announced that Amoy Diagnostics (300685.SZ) recently received an invention patent certificate issued by the Japan Patent Office. The patent is titled "Probe primer set for detecting gene mutations in myeloid leukemia based on high-throughput sequencing and its application," with patent number 7591097, classified as an invention. The patent rights are valid for twenty years from the date of application, and the patent holder is the company.

Gelonghui FinanceDec 13 16:28

Express News | A former employee of Amoy Diagnostics has been sentenced to prison for being involved in a fraud case with AstraZeneca employees.

BreakingsDec 12 12:15

PD-L1 Tests Market Research Report 2024, Featuring F. Hoffmann-La Roche, Agilent Technologies, Amoy Diagnostics, BioGenex Laboratories - Segments, Share, Regulatory, Reimbursement and Forecast to 2036 - ResearchAndMarkets.com

BusinesswireDec 5 21:19

Amoy Diagnostics (300685.SZ): has repurchased 1.17% of the shares.

Soochow Securities, November 4th | Amoy Diagnostics (300685.SZ) announced that as of October 31, 2024, the company implemented the repurchase of 4,666,240 shares through a special securities account for centralized auction trading method, accounting for 1.17% of the company's current total share capital. The highest fill price for repurchased shares was 21.91 yuan/share, and the lowest fill price was 17.20 yuan/share, with a total amount paid of 85,835,044.00 yuan (excluding transaction costs). This repurchase complies with the company's established share repurchase program and relevant legal requirements.

Gelonghui FinanceNov 4 16:56

Express News | The social security fund held positions with a market cap of nearly 190 billion yuan at the end of the third quarter.

BreakingsOct 31 07:37

Amoy Diagnostics (300685): Significant growth in Q3 24, with many indications of diagnostic products approved in Japan.

Event: The company released the third quarter report for 2024, achieving revenue of 0.305 billion yuan, a year-on-year increase of 22.53%; achieving net income attributable to the parent company of 0.083 billion yuan, a year-on-year increase of 77.58%; achieving non-net income attributable to the parent company.

everbrightOct 29 16:46

Amoy Diagnostics Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Simply Wall StOct 25 06:23

Amoy Diagnostics (300685): Performance meets expectations, innovation steadily advancing.

This report summary: In Q3, stable growth, performance meets expectations. Overseas markets and pharmaceutical business maintain rapid growth, innovative product progress smoothly, maintaining a shareholding rating. Investment highlights: maintaining a shareholding rating. Considering the significant cost reduction and efficiency improvement of the company.

gtjaOct 24 14:22

Ed Biotech: Report for the third quarter of 2024

SZSIOct 22 00:00 · Announcements

Amoy Diagnostics (300685.SZ): The net income for the first three quarters was 0.227 billion yuan, a year-on-year increase of 30.82%.

On October 21, Gelunhui announced the performance report for the third quarter of 2024. In the first three quarters of 2024, the company achieved revenue of 0.848 billion yuan, a year-on-year increase of 19.84%; net income attributable to shareholders of listed companies was 0.227 billion yuan, a year-on-year increase of 30.82%; net income profit after deducting non-recurring gains and losses was 0.212 billion yuan, a year-on-year increase of 37.74%; basic earnings per share profit was 0.57 yuan per share.

Gelonghui FinanceOct 21 16:09

Express News | Amoy Diagnostics: Net income increased by 30.82% year-on-year in the first three quarters.

BreakingsOct 21 16:04

Express News | Amoy Diagnostics: The HRD test kit has entered the special review process for innovative medical instruments.

BreakingsOct 9 11:52

Amoy Diagnostics (300685.SZ) obtained a medical device registration certificate.

Amoy Diagnostics (300685.SZ) announced that the company recently received the Medical...

Zhitong FinanceSep 6 16:23

Express News | Midday announcement: amoy diagnostics products approved in Japan; Jinwo shares planning stock-based incentive plan

BreakingsSep 5 12:02

Amoy Diagnostics (300685.SZ): The FGFR2 gene break detection kit (fluorescence in situ hybridization method) has been approved for listing in Japan.

amoy diagnostics (300685.SZ) announced that the company's self-developed FGFR2 gene breakpoint detection kit...

Zhitong FinanceSep 5 11:52

Amoy Diagnostics (300685.SZ): has repurchased 0.94% of shares.

Amoy Diagnostics (300685.SZ) announced on September 2 that as of August 31, 2024, the company repurchased 3,752,740 shares of its own stock through a repurchase special securities account using centralized auction trading. This represents 0.94% of the company's total share capital. The highest fill price for the repurchased shares was 21.91 yuan/share, and the lowest fill price was 17.20 yuan/share. The total amount paid, excluding transaction fees, was 69,458,513.60 yuan. This share repurchase complies with the company's established stock repurchase plan and relevant laws and regulations.

Gelonghui FinanceSep 2 21:33

Amoy Diagnostics (300685): The strong will always be strong in the field of tumor companion diagnostics.

Key investment points: The company focuses on the field of precise molecular diagnosis of tumors, and is a leading enterprise in China with a large number of registered diagnostic certificates for tumor companion diagnosis, a complete product line, and wide in-hospital channels. In recent years, the company has continued to launch heavyweight testing products, while also entering overseas markets.

國聯證券Sep 2 16:56

Amoy Diagnostics (300685.SZ): Currently, there are no products for detecting monkeypox virus.

Amoy Diagnostics (300685.SZ) stated on the investor interaction platform on August 21 that the company currently does not have any monkeypox virus-related detection products.

Gelonghui FinanceAug 21 16:11

Amoy Diagnostics (300685): Q2 revenue increased by 17.5% year-on-year, and cooperation with innovative drug companies continues to deepen.

The performance growth is steady, and the profit growth rate excluding stock-based incentives is higher than the income growth rate. In the first half of 2024, the company achieved a revenue of 0.543 billion (+18.4%) and a net profit attributable to the parent of 0.144 billion (+13.5%), and a non-GAAP net profit attributable to the parent.

國信證券Aug 11 00:00

Amoy Diagnostics (300685): Performance meets expectations, accompanying the development of the diagnostic leading company steadily.

Performance meets expectations with outstanding profit performance after deducting stock-based incentive costs. In 2024H1, the company achieved revenue of 0.54 billion yuan, an increase of 18.4% year on year; and achieved a net income attributable to the parent company of 0.14 billion yuan, an increase of 13.5% year on year, excluding stocks.

東方證券Aug 8 07:36